BioArctic announces that exidavnemab demonstrated good safety and tolerability in the first cohort of the Phase IIa EXIST trial for Parkinson's disease. Following positive safety evaluation, two additional cohorts with higher doses are now being initiated for both Parkinson's disease and multiple system atrophy (MSA). The study is evaluating safety, pharmacokinetics and biomarkers for slowing disease progression by targeting aggregated alpha-synuclein.
BioArctic advances phase IIa study with exidavnemab
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
